Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization

Cytoplasmic Trafficking of Nanoparticles Delivers Plasmid DNA for Macrophage Gene-Editing

(2021) So Yoon Lee et al.   CURRENT GENE THERAPY

The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice

(2021) Louise van der Weyden et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status

(2021) Shirin Karimi et al.   JOURNAL OF NEURO-ONCOLOGY

Recent trends in cancer therapy: A review on the current state of gene delivery

(2021) Esam Bashir Yahya et al.   LIFE SCIENCES

Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta‐analysis of preclinical studies

(2021) Harinad B. Maganti et al.   Stem Cells Translational Medicine

Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development

(2021) Bernarda Majc et al.   Cells

Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma

(2021) Dorothee Hölzl et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Role of TET Dioxygenases and DNA Hydroxymethylation in Bisphenols-Stimulated Proliferation of Breast Cancer Cells

(2020) Zhe Li et al.   ENVIRONMENTAL HEALTH PERSPECTIVES

Indel locations are determined by template polarity in highly efficient in vivo CRISPR/Cas9-mediated HDR in Atlantic salmon

(2020) Anne Hege Straume et al.   Scientific Reports

Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing

(2020) Hua Alexander Han et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer

(2020) Wendan Yu et al.   Cell Death & Disease

Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients

(2020) Chaojun Liu et al.   Cancer Management and Research

Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks

(2020) Han Yang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition

(2020) Lisa A. Friedman et al.   MODERN PATHOLOGY

PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity

(2020) Erin D. Lucas et al.   Cell Reports

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

(2020) Na Zhang et al.   Frontiers in Immunology

PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer

(2019) Samaresh Sau et al.   Cancers

Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing

(2019) Jose Bonafont et al.   MOLECULAR THERAPY

Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth

(2019) Jonathan B Lamano et al.   CLINICAL CANCER RESEARCH

Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells

(2019) Mingshui Chen et al.   BMC CANCER

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

(2019) Chunyang Jiang et al.   CLINICAL GENETICS

Progress Toward Long-Term Survivors of Glioblastoma

(2019) J. Nathan Cantrell et al.   MAYO CLINIC PROCEEDINGS

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

(2019) Qianqian Gao et al.   Cancer Medicine

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

(2019) Yilun Wu et al.   Frontiers in Immunology

EpCAM associates with integrin and regulates cell adhesion in cancer cells

(2019) Jie Yang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities

(2018) M. Ilie et al.   CURRENT MOLECULAR MEDICINE

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab

(2018) Olivier Bylicki et al.   OncoTargets and Therapy

Facile Gene Delivery Derived from Branched Low Molecular Weight Polyethylenimine by High Efficient Chemistry

(2018) Lei Zou et al.   Journal of Biomedical Nanotechnology

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

(2018) David Stenehjem et al.   OncoTargets and Therapy

Gene editing in T cell therapy

(2017) Yongping Zhang et al.   Journal of Genetics and Genomics

Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome

(2017) Tsubasa Miyazaki et al.   JOURNAL OF NEURO-ONCOLOGY

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

(2017) Maria Gato-Cañas et al.   Cell Reports

Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells

(2017) Wenying Huo et al.   Journal of Cancer

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma

(2017) Abhishek D. Garg et al.   OncoImmunology

CRISPR-DO for genome-wide CRISPR design and optimization

(2016) Jian Ma et al.   BIOINFORMATICS

Low Molecular Weight PEI-Based Vectors via Acid-Labile Ortho Ester Linkage for Improved Gene Delivery

(2016) Lei Zhang et al.   MACROMOLECULAR BIOSCIENCE

Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model

(2015) Danielle N. Renner et al.   Neurotherapeutics

CRISPR-STAT: an easy and reliable PCR-based method to evaluate target-specific sgRNA activity

(2015) Blake Carrington et al.   NUCLEIC ACIDS RESEARCH

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) R. Stupp et al.   ANNALS OF ONCOLOGY

Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system

(2014) Tetsushi Sakuma et al.   Scientific Reports

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis

(2013) Derek R. Johnson et al.   CANCER

Genome engineering using the CRISPR-Cas9 system

(2013) F Ann Ran et al.   Nature Protocols

High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) R. Stupp et al.   ANNALS OF ONCOLOGY

Survival comparison between glioblastoma multiforme and other incurable cancers

(2010) B. Tran et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

The Liver Is a Site for Tumor-Induced Myeloid-Derived Suppressor Cell Accumulation and Immunosuppression

(2009) Dan Ilkovitch et al.   CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY